Core Insights - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [1][2] - The company will participate in healthcare investor conferences in February, with presentations by CEO Marino Garcia [1][3] Company Overview - Dianthus Therapeutics is dedicated to designing and delivering novel, best-in-class monoclonal antibodies with enhanced selectivity and potency [2] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [2] Upcoming Events - The company will host a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6 at 9:00 a.m. ET in New York City [3] - A virtual fireside chat is scheduled for February 12 at 3:20 p.m. ET during the Oppenheimer 35th Annual Healthcare Life Sciences Conference [3]
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences